{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T16:46:00Z","timestamp":1769877960652,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007077","name":"National Institute of Biomedical Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007077","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011033","name":"Thermo Fisher Scientific","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015731","name":"Bayer Yakuhin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016288","name":"Kissei","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016288","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017193","name":"Nichi-Iko Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017193","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017346","name":"Boehringer Ingelheim Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017346","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009954","name":"Taiho Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010793","name":"Pfizer Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013172","name":"SymBio Pharmaceuticals Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013172","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jtocrr.2021.100178","type":"journal-article","created":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T03:48:04Z","timestamp":1619668084000},"page":"100178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma"],"prefix":"10.1016","volume":"2","author":[{"given":"Kazuhiko","family":"Nakagawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kijima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morihito","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Morise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoyasu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuya","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobukazu","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Takenoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yokouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Ohe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toyoaki","family":"Hida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Aoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Hirokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Matsuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaro","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taketo","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikao","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2021.100178_bib1","first-page":"544","article-title":"MPM: malignant pleural mesothelioma","volume":"1","author":"Cao","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"10.1016\/j.jtocrr.2021.100178_bib2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/carcin\/bgz004","article-title":"Prognostic factors of survival in patients with malignant pleural mesothelioma: an analysis of the National Cancer Database","volume":"40","author":"van Gerwen","year":"2019","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jtocrr.2021.100178_bib3","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: malignant pleural mesothelioma. version 1.2019. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mpm.pdf. Accessed April 4,\u00a02020."},{"key":"10.1016\/j.jtocrr.2021.100178_bib4","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","article-title":"Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT)","volume":"25","author":"Okada","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2021.100178_bib5","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A\u00a0multicentre randomised phase III trial comparing pembrolizumab vs single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9\u201315) PROMISE-meso trial","volume":"31","author":"Popat","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2021.100178_bib6","first-page":"1369","article-title":"Overexpression of CD26\/DPPIV in mesothelioma tissue and mesothelioma cell lines","volume":"26","author":"Amatya","year":"2011","journal-title":"Oncol Rep"},{"key":"10.1016\/j.jtocrr.2021.100178_bib7","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1158\/1078-0432.CCR-11-1990","article-title":"CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in malignant pleural mesothelioma","volume":"18","author":"Aoe","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2021.100178_bib8","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.bbrc.2018.08.193","article-title":"Targeting CD26 suppresses proliferation of malignant mesothelioma cell via downmodulation of ubiquitin-specific protease 22","volume":"504","author":"Okamoto","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jtocrr.2021.100178_bib9","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/bjc.2017.62","article-title":"First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers","volume":"116","author":"Angevin","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtocrr.2021.100178_bib10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.lungcan.2019.09.010","article-title":"Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma","volume":"137","author":"Takeda","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtocrr.2021.100178_bib11","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.lungcan.2011.08.011","article-title":"Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey","volume":"75","author":"Zucali","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtocrr.2021.100178_bib12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2021.100178_bib13","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1158\/1078-0432.CCR-07-0110","article-title":"Humanized anti-CD26 monoclonal antibody as a treatment for malignant\u00a0mesothelioma tumors","volume":"13","author":"Inamoto","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2021.100178_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0062304","article-title":"Nuclear localization of CD26 induced by a humanized monoclonal\u00a0antibody inhibits tumor cell growth by modulating of POLR2A transcription","volume":"8","author":"Yamada","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jtocrr.2021.100178_bib15","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.3390\/cancers11081138","article-title":"Novel antibody-drug conjugate with anti-CD26 humanized monoclonal antibody and transcription factor IIH (TFIIH) inhibitor, triptolide, inhibits tumor growth via impairing mRNA synthesis","volume":"11","author":"Hayashi","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtocrr.2021.100178_bib16","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1158\/1078-0432.CCR-06-0361","volume":"12","author":"Inamoto","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2021.100178_bib17","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/ni.3210","article-title":"DPP4 in anti-tumor immunity: going beyond the enzyme","volume":"16","author":"Ohnuma","year":"2015","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jtocrr.2021.100178_bib18","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41590-019-0321-5","article-title":"Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth","volume":"20","author":"Hollande","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jtocrr.2021.100178_bib19","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2021.100178_bib20","article-title":"The \u201cdon\u2019t eat me\u201d signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma","volume":"7","author":"Schurch","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtocrr.2021.100178_bib21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s13045-020-00989-w","article-title":"Targeting the myeloid checkpoint receptor SIRP\u03b1 potentiates innate and adaptive immune responses to promote anti-tumor activity","volume":"13","author":"Kuo","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.jtocrr.2021.100178_bib22","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jtho.2017.10.011","article-title":"Increased response rates to salvage chemotherapy administered after\u00a0PD-1\/PD-L1 inhibitors in patients with non-small cell\u00a0lung cancer","volume":"13","author":"Park","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2021.100178_bib23","article-title":"Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L)","volume":"8","author":"Kato","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jtocrr.2021.100178_bib24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.tice.2011.11.003","article-title":"Comparison of the activity levels and localization of dipeptidyl peptidase IV in normal and tumor human lung cells","volume":"44","author":"Dimitrova","year":"2012","journal-title":"Tissue Cell"},{"key":"10.1016\/j.jtocrr.2021.100178_bib25","doi-asserted-by":"crossref","first-page":"130","DOI":"10.21037\/atm.2017.03.36","article-title":"The expression of proline-specific enzymes in the human lung","volume":"5","author":"Vliegen","year":"2017","journal-title":"Ann Transl Med"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364321000370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364321000370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:35:41Z","timestamp":1762986941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364321000370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2666364321000370"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2021.100178","relation":{},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2021.100178","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"100178"}}